GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2019

Del

LYON, France, March 12, 2019 (GLOBE NEWSWIRE) --

Article 223-16 of general regulation of French Autorité des Marchés Financiers
Lyon - France

Listing markets:
Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) &
Nasdaq Global Select Market in the United-States (Symbol : ERYP)
Website : www.erytech.com

Date Total of shares composing
the share capital
Total of brut(1) voting
rights
  Total of net(2) voting
rights
 
December 31, 2018 17 940 035 19 525 606 19 523 106
January 31, 2019 17 940 035 19 525 918 19 523 418
February 28, 2019 17 940 035 19 525 792 19 523 292

        
(1)  Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on the basis of all shares carrying the single and double voting rights, including shares without voting rights.

(2)  Without treasury shares.

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease21.5.2019 14:00:00 CESTPressemelding

NEW YORK and CLEVELAND, May 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company is cleared to begin a Phase 1/2 clinical trial evaluating its novel, one-time gene therapy ABO-202 for the treatment of CLN1 disease, following acceptance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). ABO-202 is designed to deliver a functional copy of the PPT1 gene to cells of the central nervous system and peripheral organs using a combined intravenous and intrathecal delivery via the AAV9 vector. The Company will provide guidance on the timing of the clinical trial later this year. “This significant step brings hope to people impacted by this devastating disease and was achieved in partnership with Dr. Steven Gray and Taylor’s Tale,” said Timothy J. Miller, Ph.D., Co-Founder, President & Chief Scientific Officer. “We are very encouraged that ABO-202 wa

Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies21.5.2019 12:00:00 CESTPressemelding

SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Invivoscribe, Inc., a vertically integrated global company focused on Improving Lives with Precision Diagnostics ®, today announces expansion of space and testing capabilities in their international network of accredited LabPMM® clinical laboratories. Additions to the test menu will include morphology, IHC, flow cytometry, as well as the latest multiparameter flow- (MPF), and NGS-based minimal residual disease (MRD) testing of primary specimens. These new services will further support rapid patient diagnosis, study subject enrollment, and study subject stratifications. They will be available by end of this year in San Diego followed by the laboratories in Japan, Germany and China. “Our comprehensive test menu will eliminate the need for partners to split primary specimens, dramatically decreasing turnaround times and accelerating receipt of comprehensive test reports. This is especially important for partners performing international clinical

Canadian Natural Resources Limited Announces Normal Course Issuer Bid21.5.2019 11:00:00 CESTPressemelding

CALGARY, Alberta, May 21, 2019 (GLOBE NEWSWIRE) -- Canadian Natural Resources Limited ("Canadian Natural") announced today that the Toronto Stock Exchange has accepted notice filed by Canadian Natural of its intention to make a Normal Course Issuer Bid (“NCIB”) through the facilities of the Toronto Stock Exchange or other alternative Canadian trading systems. Purchases may also be made through the facilities of the New York Stock Exchange. The notice provides that Canadian Natural may, during the 12 month period commencing May 23, 2019 and ending May 22, 2020, purchase for cancellation up to 59,729,706 common shares, being 5% of the 1,194,594,136 issued and outstanding common shares as at May 10, 2019. Canadian Natural will not acquire more than 25% of the average daily trading volume of its common shares during a trading day, being 975,709 common shares subject to certain prescribed exceptions. The price which Canadian Natural will pay for any such shares will be the market price at t

Telia Norway signs partner agreement with IMImobile for Enterprise cPaaS offering21.5.2019 09:00:00 CESTPressemelding

Scandinavian telecommunications provider to resell IMImobile’s cPaaS offering, IMIconnect, to enterprise customers LONDON, May 21, 2019 (GLOBE NEWSWIRE) -- IMImobile, a global communications software provider, has signed a partner agreement with Telia Norway, with an option to extend to the wider Telia Company – the leading telecom operator in the Nordic/Baltics. The partner agreement will enable Telia to resell IMImobile’s cloud products, including its enterprise cPaaS (Communications Platform as a Service) offering, IMIconnect, to its enterprise customers. IMIconnect enables businesses to rapidly launch and orchestrate two-way, trigger-based customer communications across 10+ channels. Driven by the changes in person to person communications, consumers now expect interactions with businesses to be personalised, relevant, contextual, interactive and conducted in real time. IMImobile is helping Telia to keep pace with changing consumer expectations and offer innovative communications s

GridGain Joins Cloud Native Computing Foundation21.5.2019 09:00:00 CESTPressemelding

Increasingly Deployed in the Cloud, GridGain Looks to Contribute to Growing Body of Cloud Native Best Practices FOSTER CITY, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite™, today announced it has joined the Cloud Native Computing Foundation® (CNCF®) and The Linux Foundation. GridGain is demonstrating its support for the CNCF with a Silver Membership and participating in the foundation’s programs and guidance related to supporting cloud native applications. CNCF is an open source software foundation dedicated to making cloud native computing universal and sustainable. CNCF has over 400 members including the world’s largest public cloud and enterprise software companies as well as dozens of innovative startups. Cloud-native computing uses an open source software stack to deploy applications as microservices, packaging each part into its own container, and dynamically orchestrating those conta

Melissa Showcases All-in-One Identity Verification at Money20/20 Europe21.5.2019 07:00:00 CESTPressemelding

Demos Highlight How to Combat Fraud, Minimise Risk and False Positives, and Maintain Compliance During Frictionless Customer Experience LONDON, May 20, 2019 (GLOBE NEWSWIRE) -- Melissa, a leading provider of global contact data quality and identity verification (IDV) solutions, will demonstrate its all-in-one cloud IDV and enrichment solution at Money20/20 Europe, stand B91. Melissa’s IDV technology operates side-by-side with existing banking and payments software platforms, seamlessly verifying identity using a global dataset of billions of records. In real time and in compliance with the full spectrum of banking regulations and data standards, financial institutions are empowered with trusted banking relationships – combatting fraud and reducing friction in the customer experience. Melissa works with organisations globally to unlock the value of accurate customer data, including Bank of America, Creditsafe, MetaBank, Tranzfar, BAE Systems, GSK, car2go, Microsoft, the NHS, and the For